Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy: Final appraisal document

DRAFT guidance does not recommend this use of pembrolizumab, within its marketing authorisation, as the most plausible cost-effectiveness estimate remains above what NICE normally considers acceptable for end-of-life treatments.


National Institute for Health and Care Excellence